{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000480","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.115071+00:00","generated_at":"2026-06-07T04:25:07.629100+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead prices 15.79M share offering at $28.50, expects net proceeds of $429.0M","bullets":["Sales of 15,790,000 shares at $28.50/share; net proceeds ~$429.0M after discounts and expenses.","Underwriters include Jefferies, BofA Securities, and Cowen and Company as representatives.","Proceeds allocated to R&D, general corporate expenses, and working capital needs.","Offering expected to close on January 5, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000480","json":"https://secwatch.observer/filing/0001628280-24-000480.json","markdown":"https://secwatch.observer/filing/0001628280-24-000480.md","text":"https://secwatch.observer/filing/0001628280-24-000480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/0001628280-24-000480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/arwr-20240102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:25:07.629100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf81017456afacefd5ed8281da058de9c9d42854","claim":"ARROWHEAD PHARMACEUTICALS, INC. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $429.0 million (effective 2024-01-02).","evidence_excerpt":"On January 2, 2024, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 15,790,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share at an offering price of $28.50 per Share (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/0001628280-24-000480-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters"},{"label":"Value","value":"approximately $429.0 million"},{"label":"Effective","value":"2024-01-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}